The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV1. We hypothesized that a multidimensional grading system that assessed the respiratory and systemic expressions of COPD would better categorize and predict outcome in these patients. METHODS: We first evaluated 207 patients and found that four factors predicted the risk of death in this cohort: the body-mass index (B), the degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), measured by the six-minute-walk test. We used these variables to construct the BODE index, a multidimensional 10-point scale in which higher scores indicate a higher risk of death. We then prospectively validated the index in a cohort of 625 patients, with death from any cause and from respiratory causes as the outcome variables. RESULTS: There were 25 deaths among the first 207 patients and 162 deaths (26 percent) in the validation cohort. Sixty-one percent of the deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infarction, 12 percent to lung cancer, and 13 percent to other causes. Patients with higher BODE scores were at higher risk for death; the hazard ratio for death from any cause per one-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001). The C statistic for the ability of the BODE index to predict the risk of death was larger than that for the FEV1 (0.74 vs. 0.65). CONCLUSIONS: The BODE index, a simple multidimensional grading system, is better than the FEV1 at predicting the risk of death from any cause and from respiratory causes among patients with COPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [166]
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043
Lung Function Testing: Selection of Reference Values and Interpretative Strategies
(1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.5.1202 · Cited by 2,510
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
Evaluation of Clinical Methods for Rating Dyspnea
Mahler, D. A., & Wells, C. K. (1988) · Chest · doi:10.1378/chest.93.3.580 · Cited by 1,822
Research works printed but not linked: 1
- Burrows B, 1991, Eur Respir Rev, 1, 340
Cited by
Items 201–300 of 1,007
Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
Casanova, C., Celli, B. R., de-Torres, J. P., Martínez-Gonzalez, C., Cosio, B. G., Pinto-Plata, V., de Lucas-Ramos, P., Divo, M., Fuster, A., Peces-Barba, G., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01162-2017 · Cited by 181
Self-citationAgusti, A., Sobradillo, P., & Celli, B. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1414pp · Cited by 186
Self-citationLainscak, M., von Haehling, S., Doehner, W., Sarc, I., Jeric, T., Ziherl, K., Kosnik, M., Anker, S. D., & Suskovic, S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0023-9 · Cited by 179
“The BODE composite score [23] is allegedly the most frequently used in everyday practice but it is primarily limited to patients with clinically stable disease as seen in outpatient setting.”
BackgroundMethodChan, S. M. H., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.013 · Cited by 177
“Alternative assessments, such as the BODE Index (Body mass index, airflow Obstruction, Dyspnoea and Exercise capacity index in COPD), have been proposed and may offer a more comprehensive measure of severity as they also take into account systemic manifestations that are not reflected by the FEV 1 (Celli et al., 2004)…”
Depressive Symptoms as Predictors of Mortality in Patients With COPD
de Voogd, J. N., Wempe, J. B., Koëter, G. H., Postema, K., van Sonderen, E., Ranchor, A. V., Coyne, J. C., & Sanderman, R. (2009) · Chest · doi:10.1378/chest.08-0078 · Cited by 186
Vogelmeier, C., Buhl, R., Burghuber, O., Criée, C.-P., Ewig, S., Godnic-Cvar, J., Hartl, S., Herth, F., Kardos, P., Kenn, K., et al. (2018) · Pneumologie · doi:10.1055/s-0043-125031 · Cited by 161
“[40] Celli BR, Cote CG, Marin JM et al.”
Kim, V., & Aaron, S. D. (2018) · European Respiratory Journal · doi:10.1183/13993003.01261-2018 · Cited by 179
Forced vital capacity, airway obstruction and survival in a general population sample from the USA
Burney, P. G. J., & Hooper, R. (2011) · Thorax · doi:10.1136/thx.2010.147041 · Cited by 182
“rather than a measure of air flow obstruction predicts the prognosis of airway obstruction.”
BackgroundPrevalence and Determinants of COPD in Spain: EPISCAN II
Soriano, J. B., Alfageme, I., Miravitlles, M., de Lucas, P., Soler-Cataluña, J. J., García-Río, F., Casanova, C., Rodríguez González-Moro, J. M., Cosío, B. G., Sánchez, G., et al. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2020.07.024 · Cited by 166
Self-citationThe 6-min walking distance: long-term follow up in patients with COPD
Casanova, C., Cote, C. G., Marin, J. M., de Torres, J. P., Aguirre-Jaime, A., Mendez, R., Dordelly, L., & Celli, B. R. (2007) · European Respiratory Journal · doi:10.1183/09031936.00071506 · Cited by 173
“he 6-min walking distance (6MWD) test has gained importance in the assessment of functional exercise capacity in patients with chronic obstructive pulmonary disease (COPD) [ 1 , 2] and other respiratory diseases, such as pulmonary hypertension [3], interstitial lung disease [4], cystic fibrosis [5] and post-acute resp…”
BackgroundMethodInfluentialSelf-citationThe potential impact of anaemia of chronic disease in COPD
Similowski, T., Agustí, A., MacNee, W., & Schönhofer, B. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00143704 · Cited by 179
“... emphasised haematocrit as an independent and major predictor of survival, with the 3-yr survival rate decreasing as lower haematocrit values were considered, and polycythaemia being associated with higher survival rates (3-yr survival 24% (95% confidence interval (CI) 16–33%) when haematocrit was ,35% versus 70% (…”
BackgroundHow does comorbidity influence survival in idiopathic pulmonary fibrosis?
Hyldgaard, C., Hilberg, O., & Bendstrup, E. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.01.008 · Cited by 180
“In COPD, a newly introduced comorbidity index, the COTE index [30], identified 12 comorbidities that confer an independent risk of death in COPD patients and complements the BODE index [31] in prediction of survival.”
Lung function decline and outcomes in an elderly population
Mannino, D. M. (2006) · Thorax · doi:10.1136/thx.2005.052449 · Cited by 180
“Recently, the body mass, obstruction, dyspnea, and exercise (BODE) index was evaluated by Celli and colleagues and found to be of greater predictive value than FEV1 alone ( 6 ).”
BackgroundMethodProspective study of dietary patterns and chronic obstructive pulmonary disease among US men
Varraso, R., Fung, T. T., Hu, F. B., Willett, W., & Camargo, C. A. (2007) · Thorax · doi:10.1136/thx.2006.074534 · Cited by 174
Guo, Y., Zhang, T., Wang, Z., Yu, F., Xu, Q., Guo, W., Wu, C., & He, J. (2016) · Medicine · doi:10.1097/md.0000000000004225 · Cited by 170
The prevalence of small airways disease in adult asthma: A systematic literature review
Usmani, O. S., Singh, D., Spinola, M., Bizzi, A., & Barnes, P. J. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.05.006 · Cited by 170
Body Mass and Fat-Free Mass Indices in COPD
Ischaki, E., Papatheodorou, G., Gaki, E., Papa, I., Koulouris, N., & Loukides, S. (2007) · Chest · doi:10.1378/chest.06-2789 · Cited by 165
Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema
Spira, A., Beane, J., Pinto-Plata, V., Kadar, A., Liu, G., Shah, V., Celli, B., & Brody, J. S. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0273oc · Cited by 174
“These peripheral manifestations are so important that an integrative clinical score that includes BMI, degree of obstruction, perception of dyspnea, and the 6 min walk distance (also known as the BODE index) proved to be an excellent predictor of mortality in a large cohort of patients followed for 5 yr (15).”
BackgroundMethodInfluentialSelf-citationSex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease
Fan, V. S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.21.2345 · Cited by 171
Funk, G.-C., Kirchheiner, K., Chris Burghuber, O., & Hartl, S. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-1 · Cited by 168
“For calculation of the BODE index, we used the empirical model as previously described [24]: for each threshold value of FEV1%predicted, distance walked in six minutes, and score on the MMRC dyspnoea scale [28], the patients received points ranging from 0 (lowest value) to 3 (maximal value).”
BackgroundMethodInfluentialBody composition and functional limitation in COPD
Eisner, M. D., Blanc, P. D., Sidney, S., Yelin, E. H., Lathon, P. V., Katz, P. P., Tolstykh, I., Ackerson, L., & Iribarren, C. (2007) · Respiratory Research · doi:10.1186/1465-9921-8-7 · Cited by 163
Tsiligianni, I. G., van der Molen, T., Moraitaki, D., Lopez, I., Kocks, J. W., Karagiannis, K., Siafakas, N., & Tzanakis, N. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-20 · Cited by 168
“The BODEindex is a grading system developed to predict mortality in COPD [15].”
BackgroundMethodInfluentialGuía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC
Peces-Barba, G., Albert Barberà, J., Agustí, À., Casanova, C., Casas, A., Luis Izquierdo, J., Jardim, J., Varela, V. L., Monsó, E., Montemayor, T., et al. (2008) · Archivos de Bronconeumología · doi:10.1157/13119943 · Cited by 168
Self-citationChronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic
Barnes, P. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040112 · Cited by 165
“, exercise capacity, exacerbation frequency, and systemic features all indicate a poor prognosis [”
BackgroundWaschki, B., Spruit, M. A., Watz, H., Albert, P. S., Shrikrishna, D., Groenen, M., Smith, C., Man, W. D.-C., Tal-Singer, R., Edwards, L. D., et al. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.022 · Cited by 170
C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD
de Torres, J. P., Pinto-Plata, V., Casanova, C., Mullerova, H., Córdoba-Lanús, E., de Fuentes, M. M., Aguirre-Jaime, A., & Celli, B. R. (2008) · Chest · doi:10.1378/chest.07-2433 · Cited by 169
Self-citationNguyen, H. Q., Donesky-Cuenco, D., Wolpin, S., Reinke, L. F., Benditt, J. O., Paul, S. M., & Carrieri-Kohlman, V. (2008) · Journal of Medical Internet Research · doi:10.2196/jmir.990 · Cited by 162
“Participants who dropped out after randomization (n = 11; 36% due to technical difficulties) were similar in age, education, employment status, distance from home to the respective clinical site, pulmonary functioning, disease severity (measured by the BODE composite index, which includes body mass index [BMI], FEV1,…”
BackgroundZinellu, A., Collu, C., Nasser, M., Paliogiannis, P., Mellino, S., Zinellu, E., Traclet, J., Ahmad, K., Mangoni, A. A., Carru, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184134 · Cited by 193
“6MWT: six-minute walk test; AISI: Aggregate Systemic Inflammation Index; COPD: chronic obstructive pulmonary disease; DLCO: diffusion lung carbon oxide; dNLR: derived neutrophil-to-lymphocyte ratio; FEV1: forced expiratory volume in the 1st second; FVC: forced vital capacity; LMR: lymphocyte-to-monocytes ratio; NLR: n…”
BackgroundAssociation between markers of emphysema and more severe chronic obstructive pulmonary disease
Boschetto, P., Quintavalle, S., Zeni, E., Leprotti, S., Potena, A., Ballerin, L., Papi, A., Palladini, G., Luisetti, M., Annovazzi, L., et al. (2006) · Thorax · doi:10.1136/thx.2006.058321 · Cited by 168
“The BODE index (body mass index, airflow obstruction, dyspnoea, exercise performance) and the inspiratory capacity to total lung capacity ratio (IC/TLC) have recently been reported to grade the severity of COPD as a systemic and respiratory disease and to predict the outcome in these patients.”
BackgroundLaurin, C., Lavoie, K. L., Bacon, S. L., Dupuis, G., Lacoste, G., Cartier, A., & Labrecque, M. (2007) · Chest · doi:10.1378/chest.07-0134 · Cited by 168
Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
Miravitlles, M., Soler-Cataluña, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., Riesco, J. A., Trigueros, J. A., Piñera, P., Simón, A., et al. (2012) · Archivos de Bronconeumología (English Edition) · doi:10.1016/j.arbr.2012.05.003 · Cited by 167
A Randomized Trial to Improve Communication About End-of-Life Care Among Patients With COPD
Au, D. H., Udris, E. M., Engelberg, R. A., Diehr, P. H., Bryson, C. L., Reinke, L. F., & Curtis, J. R. (2012) · Chest · doi:10.1378/chest.11-0362 · Cited by 163
Sit-to-stand tests for COPD: A literature review
Vaidya, T., Chambellan, A., & de Bisschop, C. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.003 · Cited by 165
Karch, A., Vogelmeier, C., Welte, T., Bals, R., Kauczor, H.-U., Biederer, J., Heinrich, J., Schulz, H., Gläser, S., Holle, R., et al. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.03.008 · Cited by 162
What is early COPD and why is it important?
Soriano, J. B., Polverino, F., & Cosío, B. G. (2018) · European Respiratory Journal · doi:10.1183/13993003.01448-2018 · Cited by 179
Puhan, M. A. (2005) · Thorax · doi:10.1136/thx.2004.033274 · Cited by 163
The obesity paradox in the surgical population
Valentijn, T. M., Galal, W., Tjeertes, E. K. M., Hoeks, S. E., Verhagen, H. J., & Stolker, R. J. (2013) · The Surgeon · doi:10.1016/j.surge.2013.02.003 · Cited by 160
“However, low BMI in COPD has also been shown to be a risk factor for mortality, irrespective of disease severity.(87) In addition, skeletal muscle dysfunction is a common feature”
Shah, T., Press, V. G., Huisingh-Scheetz, M. J., & White, S. R. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.002 · Cited by 185
“Low BMI, a key factor in COPD mortality, was correlated with increased readmission risk, but it is not clear whether this relationship is causal or (more likely) whether patients with low BMI have more severe disease.(50) Black race was shown to confer increased risk of readmission after adjustment for socioeconomic s…”
BackgroundStorgaard, L. H., Hockey, H., Laursen, B. S., & Weinreich, U. M. (2018) · International Journal of COPD · doi:10.2147/copd.s159666 · Cited by 164
“37 This study demonstrates that the long-term HFNC treatment decelerates disease progression, as seen with 6MWD, QoL and PaCO 2 .”
Depression and Functional Status Are Strongly Associated With Dyspnea in Interstitial Lung Disease
Ryerson, C. J., Berkeley, J., Carrieri‐Kohlman, V., Pantilat, S. Z., Landefeld, C. S., & Collard, H. R. (2010) · CHEST Journal · doi:10.1378/chest.10-0608 · Cited by 174
Bhatt, S. P., Washko, G. R., Hoffman, E. A., Newell, J. D., Bodduluri, S., Diaz, A. A., Galban, C. J., Silverman, E. K., San José Estépar, R., & Lynch, D. A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1351so · Cited by 158
Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
Sharafkhaneh, A., Southard, J. G., Goldman, M., Uryniak, T., & Martin, U. J. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2011.07.020 · Cited by 160
“Additional secondary variables included the BODE index, which is a composite of body mass index, airflow obstruction (percentage of predicted FEV1), dyspnea (Modified Medical Research Council scale(16)), and exercise capacity (6min walk test).(17) Health-related quality of life was assessed using the St.”
MethodRecent advances in pre-clinical mouse models of COPD
Vlahos, R., & Bozinovski, S. (2013) · Clinical Science · doi:10.1042/cs20130182 · Cited by 176
Multiple biomarkers predict disease severity, progression and mortality in COPD
Zemans, R. L., Jacobson, S. R., Keene, J., Kechris, K. J., Miller, B. E., Tal‐Singer, R., & Bowler, R. P. (2017) · Respiratory Research · doi:10.1186/s12931-017-0597-7 · Cited by 168
“BMI, airflow limitation, dyspnea, and exercise capacity (BODE), are moderately predictive of mortality in COPD [6, 7].”
BackgroundShort telomere length, lung function and chronic obstructive pulmonary disease in 46 396 individuals
Rode, L., Bojesen, S. E., Weischer, M., Vestbo, J., & Nordestgaard, B. G. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202544 · Cited by 153
Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study
Garcia-Vidal, C., Almagro, P., Romaní, V., Rodríguez-Carballeira, M., Cuchi, E., Canales, L., Blasco, D., Heredia, J. L., & Garau, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00003309 · Cited by 154
Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema
Snell, G. I., Herth, F. J. F., Hopkins, P. M.-A., Baker, K. M., Witt, C. C., Gotfried, M. H., Valipour, A., Wagner, M., Stanzel, F., Egan, J. J., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00092411 · Cited by 156
“In addition to the efficacy endpoints described in the Study Design section, the BODE index was calculated.(20) Safety Assessments.”
MethodBellia, V., Pedone, C., Catalano, F., Zito, A., Davià, E., Palange, S., Forastiere, F., & Incalzi, R. A. (2007) · CHEST Journal · doi:10.1378/chest.06-2824 · Cited by 162
Labaki, W. W., Martínez, C. H., Martínez, F. J., Galbán, C. J., Ross, B. D., Washko, G. R., Barr, R. G., Regan, E. A., Coxson, H. O., Hoffman, E. A., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201703-0451pp · Cited by 167
“This association further supports the known relationship between worse emphysema and higher scores on the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index, which is a well-validated predictor of mortality in subjects with COPD (41, 45, 70).”
Predictors of Survival in COPD: More than Just the FEV1
Celli, B. R., Côté, C., Lareau, S. C., & Meek, P. (2008) · Respiratory Medicine · doi:10.1016/s0954-6111(08)70005-2 · Cited by 172
Self-citationCrim, C. C., Dransfield, M. T., Bourbeau, J., Jones, P., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martínez, F. J., Barnhart, F., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201409-413oc · Cited by 153
Yamaguti, W. P. S., Barbosa, R. C. C., Neto, A. P., Chammas, M. C., Gomes, A. C., Salge, J. M., Moriya, H. T., Cukier, A., & Carvalho, C. R. F. (2012) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2011.11.026 · Cited by 154
“The body mass index, airflow obstruction, dyspnea, and exercise capacity values were integrated into a score—the BODE index.(36)”
MethodPillai, S. G., Kong, X., Edwards, L. D., Cho, M. H., Anderson, W. H., Coxson, H. O., Lomas, D. A., & Silverman, E. K. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0151oc · Cited by 153
“The body mass index, airflow obstruction, and exercise capacity (BODE) index was calculated using the method previously described (16).”
MethodPredictors of outcomes in COPD exacerbation cases presenting to the emergency department
Roche, N., Zureik, M., Soussan, D., Neukirch, F., & Perrotin, D. (2008) · European Respiratory Journal · doi:10.1183/09031936.00129507 · Cited by 151
Shavelle, R., Strauss, D., Paculdo, D. R., Kush, & Mannino, D. M. (2009) · International Journal of COPD · doi:10.2147/copd.s5237 · Cited by 178
Güell, M.-R., Cejudo, P., Ruiz, F. Ó., Puy, M. C., Rodríguez-Trigo, G., Pijoán, J. I., Martínez‐Indart, L., Gorostiza, A., Bdeir, K., Celli, B. R., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201603-0602oc · Cited by 216
Self-citationPrediction of risk of COPD exacerbations by the BODE index
Marín, J. M., Carrizo, S. J., Casanova, C., Martínez‐Camblor, P., Soriano, J. B., Agustí, A. G. N., & Celli, B. R. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.10.004 · Cited by 147
Self-citationEffect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease
Valerio, G., Bracciale, P., & D'Agostino, A. G. (2009) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808103499 · Cited by 147
Body mass index in male patients with COPD: correlation with low attenuation areas on CT
Ogawa, E., Nakano, Y., Ohara, T., Muro, S., Hirai, T., Satô, S., Sakai, H., Tsukino, M., Kinose, D., Nishioka, M., et al. (2008) · Thorax · doi:10.1136/thx.2008.097543 · Cited by 146
Activity Monitoring and Energy Expenditure in COPD Patients: A Validation Study
Patel, S. A., Benzo, R. P., Slivka, W. A., & Sciurba, F. C. (2007) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550701246658 · Cited by 144
Manifestações sistêmicas na doença pulmonar obstrutiva crônica
Dourado, V. Z., Tanni, S. É., do Vale, S. A., Faganello, M. M., Sanchez, F. F., & Godoy, I. (2006) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132006000200012 · Cited by 230
“... stress and inflammation might be involved in the mechanisms of development of the systemic effects of COPD.(4) Patients with COPD present weight loss, which is an independent indicator of disease outcome.(5) Loss of lean body mass also results in peripheral muscle dysfunction, reduction in exercise tolerance and l…”
BackgroundShort- and Medium-term Prognosis in Patients Hospitalized for COPD Exacerbation
Almagro, P., Soriano, J. B., Cabrera, F. J., Boixeda, R., Ortiz, M. B. A., Barreiro, B., Díez‐Manglano, J., Murio, C., & Heredia, J. L. (2013) · CHEST Journal · doi:10.1378/chest.13-1328 · Cited by 143
Vestbo, J., Agustí, A. G. N., Wouters, E. F. �., Bakke, P. S., Calverley, P. M. A., Celli, B. R., Coxson, H. O., Crim, C. C., Edwards, L. D., Locantore, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201311-2006pp · Cited by 143
Self-citationWickerson, L., Rozenberg, D., Janaudis-Ferreira, T., Deliva, R., Lo, V., Beauchamp, G., Helm, D., Gottesman, C., Mendes, P., Vieira, L., et al. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i3.517 · Cited by 136
Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity
Guðmundsson, G., Gíslason, Þ., Lindberg, E., Hallin, R., Ulrik, S. C., Brøndum, E., Nieminen, M. M., Aine, T., Bakke, P. S., & Janson, C. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-109 · Cited by 143
“tidimensional grading systems are better than FEV1 to predict the risk of death [31].”
BackgroundAtelectasis and survival after bronchoscopic lung volume reduction for COPD
Hopkinson, N. S., Kemp, S. V., Toma, T. P., Hansell, D. M., Geddes, D. M., Shah, P. L., & Polkey, M. I. (2010) · European Respiratory Journal · doi:10.1183/09031936.00100110 · Cited by 142
Puhan, M. A., Büsching, G., Schünemann, H. J., vanOort, E., Zaugg, C., & Frey, M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-11-200612050-00006 · Cited by 135
Predicting outcomes following hospitalization for acute exacerbations of COPD
Steer, J., Gibson, G. J., & Bourke, S. C. (2010) · QJM · doi:10.1093/qjmed/hcq126 · Cited by 152
“As no single index accurately and reliably predicts mortality, prognostic tools derived from several indices have been developed.(15,16) One example is the BODE index(15) that, in stable disease, is a better predictor of mortality than FEV1 alone.”
MethodThe Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study
Adibi, A., Sin, D. D., Safari, A., JOHNSON, K., Aaron, S. D., FitzGerald, J. M., & Sadatsafavi, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30397-2 · Cited by 157
Spirometry Use in Clinical Practice Following Diagnosis of COPD
Lee, T. A., Bartle, B., & Weiss, K. B. (2006) · CHEST Journal · doi:10.1378/chest.129.6.1509 · Cited by 141
Lung Function Decline and Outcomes in an Adult Population
Mannino, D. M., Reichert, M. M., & Davis, K. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1344oc · Cited by 152
Clinical characteristics and prognosis of chronic pulmonary aspergillosis
Ohba, H., Miwa, S., Shirai, M., Kanai, M., Eifuku, T., Suda, T., Hayakawa, H., & Chida, K. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.01.014 · Cited by 139
“Several studies have shown that a low BMI is associated with increased mortality in those patients.(16,17) In our study, low BMI was demonstrated to have an independent effect on mortality in CPA patients.”
BackgroundBeauchamp, M., Evans, R. A., Janaudis‐Ferreira, T., Goldstein, R. S., & Brooks, D. (2013) · CHEST Journal · doi:10.1378/chest.12-2421 · Cited by 148
Koblížek, V., Chlumský, J., Zindr, V., Neumannová, K., Zatloukal, J., Žák, J., Sedlák, V., Kocianova, J., Zatloukal, J., Hejduk, K., et al. (2013) · Biomedical Papers · doi:10.5507/bp.2013.039 · Cited by 151
Sex differences between women and men with COPD: A new analysis of the 3CIA study
Alonso, T., Castillo, E. G., Ancochea, J., Sanz, M. T. P., Almagro, P., Martínez‐Camblor, P., Miravitlles, M., Rodríguez‐Carballeira, M., Navarro, A., Lamprecht, B., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106105 · Cited by 137
Self-citationBody weight and comorbidity predict mortality in COPD patients treated with oxygen therapy
Martí, S., Muñoz, X., Ríos, J., Morell, F., & Ferrer, J. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00076405 · Cited by 159
Laviolette, L., Bourbeau, J., Bernard, S., Lacasse, Y., Pepin, V., Breton, M.-J., Baltzan, M., Rouleau, M., & Maltais, F. (2007) · Thorax · doi:10.1136/thx.2006.076844 · Cited by 133
Phenotypes of Chronic Obstructive Pulmonary Disease
Friedlander, A. L., Lynch, D. A., Dyar, L. A., & Bowler, R. P. (2007) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550701629663 · Cited by 152
“This increased understanding that patients with COPD have systemic manifestations that are not reflected by the FEV1 have led to multidimensional grading systems to better categorize and predict outcomes (13).”
BackgroundSex differences in mortality in patients with COPD
de-Torres, J. P., Côté, C., López, M. V., Casanova, C., Orlando Díaz, P., Marín, J. M., Pinto-Plata, V., de Oca, M. M., Nekach, H., Dordelly, L. J., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00096108 · Cited by 139
Self-citationModels of chronic obstructive pulmonary disease
Groneberg, D. A., & Chung, K. F. (2004) · Respiratory Research · doi:10.1186/1465-9921-5-18 · Cited by 160
“O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8 T lymphocytes with FEV1.”
InfluentialEATON, T., YOUNG, P., FERGUSSON, W., MOODIE, L., ZENG, I., O'KANE, F., GOOD, N., RHODES, L., POOLE, P., & KOLBE, J. (2009) · Respirology · doi:10.1111/j.1440-1843.2008.01418.x · Cited by 132
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Buhl, R., Dunn, L. J., Disdier, C., Lassen, C., Amos, C., Henley, M., & Kramer, B. (2011) · European Respiratory Journal · doi:10.1183/09031936.00191810 · Cited by 142
Chronic Obstructive Pulmonary Disease: A Chronic Systemic Inflammatory Disease
van Eeden, S. F., & Sin, D. D. (2007) · Respiration · doi:10.1159/000111820 · Cited by 168
“Collectively, these studies support the concept of a common systemic inflammatory process linking COPD and type II diabetes. Systemic Response in COPD and MortalityAlthough decline in FEV 1 correlates well with survival in COPD, it has been increasingly recognized that extrapulmonary manifestations of COPD have a sign…”
MethodMarkers of disease severity in chronic obstructive pulmonary disease
Franciosi, L. G., Page, C. P., Celli, B. R., Cazzola, M., Walker, M. J., Danhof, M., Rabe, K. F., & Pasqua, O. E. D. (2005) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.05.001 · Cited by 138
“the BODE index that combines body-mass index, airflow obstruction, dyspnea, and exercise capacity [57]) will also be examined for disease classification.”
Self-citationThe modified BODE index: validation with mortality in COPD
Côté, C., Pinto-Plata, V., Marín, J. M., Nekach, H., Dordelly, L. J., & Celli, B. R. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138507 · Cited by 152
“The BODE index, which incorporates measurements of nutrition (BMI or Body Mass Index), air flow obstruction (FEV1), dyspnea (The Modified Medical Research Council Dyspnea Scale or MMRC) and exercise capacity as measured by the 6MWD predicts mortality (16, 17), hospitalizations (18) and reflects disease modification af…”
MethodSelf-citationJaitovich, A., Angulo, M., Lecuona, E., Dada, L. A., Welch, L. C., Cheng, Y., Gusarova, G., Ceco, E., Liu, C., Shigemura, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.625715 · Cited by 137
“Muscle atrophy is being increasingly recognized as a major contributor to worse clinical outcomes in patients with pulmonary diseases (4, 37, 38), and indeed recovery of lower limbs muscle mass of COPD patients in the setting of pulmonary rehabilitation has proven to be beneficial (39).”
BackgroundBronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa
Millares, L., Ferrari, R., Gallego, M., Garcia-Nuñez, M., Pérez-Brocal, V., Espasa, M., Pomares, X., Monton, C., Moya, A., & Monsó, E. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2044-0 · Cited by 136
“Sputum has traditionally been used for the identification of bronchial infection by potentially pathogenic microorganisms (PPMs) in exacerbated chronic obstructive pulmonary disease (COPD) patients, and positive cultures are found in a significant proportion of patients in this clinical setting, Haemophilus influenzae…”
BackgroundChronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony
Mirrakhimov, A. E. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-132 · Cited by 148
“It is well known, that a low BMI in patients with COPD is considered to be a risk factor for all cause related and pulmonary related mortality [32].”
BackgroundShephard, R. J. (2012) · Yearbook of Sports Medicine · doi:10.1016/j.yspm.2011.09.013 · Cited by 135
Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts
Keene, J., Jacobson, S. R., Kechris, K. J., Kinney, G. L., Foreman, M. G., Doerschuk, C. M., Make, B. J., Curtis, J. L., Rennard, S. I., Barr, R. G., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1330oc · Cited by 147
“Definition of abbreviations: ATS = American Thoracic Society; BMI = body mass index; BODE = BMI, airflow obstruction, dyspnea, and exercise index (42);”
BackgroundVerberkt, C. A., Everdingen, M. H. J. V. D. B.-V., Schols, J. M. G. A., Hameleers, N., Wouters, E. F. �., & Janssen, D. J. A. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3134 · Cited by 134
“Rheumatologic disease 1 (2) 3 (5) 0 2 (8)”
Update on the management of COPD.
Celli, B. (2008) · Chest · doi:10.1378/chest.07-2061 · Cited by 150
Self-citationDecramer, M., Benedetto, F. D., Ponte, A. D., & Marinari, S. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.09.010 · Cited by 133
Walking versus Cycling: Sensitivity to Bronchodilation in Chronic Obstructive Pulmonary Disease
Pepin, V., Saey, D., Whittom, F., LeBlanc, P., & Maltais, F. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1037oc · Cited by 133
Casanova, C., Marín, J. M., González, C. M., de Lucas‐Ramos, P., Mir-Viladrich, I., Cosío, B. G., Peces‐Barba, G., Solanes, I., Agüero, R., Collado, N. F., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-2449 · Cited by 134
Self-citationDepression and Health-Related Quality of Life in Chronic Obstructive Pulmonary Disease
Omachi, T. A., Katz, P. P., Yelin, E. H., Gregorich, S. E., Iribarren, C., Blanc, P. D., & Eisner, M. D. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.036 · Cited by 128
High-risk patients following hospitalisation for an acute exacerbation of COPD
Piquet, J., Chavaillon, J.-M., David, P., Martin, F., Blanchon, F., & Roche, N. (2013) · European Respiratory Journal · doi:10.1183/09031936.00180312 · Cited by 150
Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease
Kennedy, C. C., Novotny, P. J., LeBrasseur, N. K., Wise, R. A., Sciurba, F. C., & Benzo, R. P. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201803-175oc · Cited by 140
Budweiser, S., Jörres, R. A., Riedl, T., Heinemann, F., Hitzl, A. P., Windisch, W., & Pfeifer, M. (2007) · CHEST Journal · doi:10.1378/chest.06-2124 · Cited by 146
Machine Learning and Prediction of All-Cause Mortality in COPD
Moll, M. R., Qiao, D., Regan, E. A., Hunninghake, G. M., Make, B. J., Tal‐Singer, R., McGeachie, M. J., Castaldi, P. J., Estépar, R. S. J., Washko, G. R., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.079 · Cited by 133
Self-citation
Metadata
- Authors
- Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J.
- Affiliations
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital Clínico Universitario de Caracas (VE)
- Boston University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 1005-1012
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139347600
- Semantic Scholar
- 12606ed46f2e1cd6f56b679b445a8fda29690f65
- Cited by
- 4,015
- References
- 36
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 153 · 2023: 132 · 2022: 124 · 2021: 176 · 2020: 199 · 2019: 158 · 2018: 192 · 2017: 184 · 2016: 206 · 2015: 185 · 2014: 241 · 2013: 230 · 2012: 242
- FWCI
- 135.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- chronic obstructive pulmonary disease, BODE index, body mass index, airflow obstruction, dyspnea, exercise capacity, 6-minute walk test, mortality prediction, FEV1, disease severity classification, respiratory mortality
- MeSH terms
- Aged, Airway Obstruction, Dyspnea, Forced Expiratory Volume, Humans, Middle Aged, Prospective Studies, Risk, Risk Factors, Severity of Illness Index, Body Mass Index, Exercise Tolerance, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.